# ASPRIA (NCT04434040)

> Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04434040
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA
- Interventions: Atezolizumab; Sacituzumab govitecan
- Enrollment: 40
- Primary outcome: Rate of undetectable circulating tumor cfDNA- 6 Cycles

## Indexed commentary on ASPRIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 3
- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aspria-nct04434040